- Home
- BEAM vs VITL Comparison
BEAM vs VITL Comparison
Compare BEAM & VITL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- VITL
- Stock Information
- Founded
- BEAM 2017
- VITL 2007
- Country
- BEAM United States
- VITL United States
- Employees
- BEAM N/A
- VITL N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- VITL Packaged Foods
- Sector
- BEAM Health Care
- VITL Consumer Staples
- Exchange
- BEAM Nasdaq
- VITL Nasdaq
- Market Cap
- BEAM 1.7B
- VITL 1.6B
- IPO Year
- BEAM 2020
- VITL 2020
- Fundamental
- Price
- BEAM $17.46
- VITL $47.70
- Analyst Decision
- BEAM Strong Buy
- VITL Strong Buy
- Analyst Count
- BEAM 10
- VITL 9
- Target Price
- BEAM $48.56
- VITL $46.89
- AVG Volume (30 Days)
- BEAM 2.4M
- VITL 1.1M
- Earning Date
- BEAM 08-05-2025
- VITL 08-07-2025
- Dividend Yield
- BEAM N/A
- VITL N/A
- EPS Growth
- BEAM N/A
- VITL 5.37
- EPS
- BEAM N/A
- VITL 1.13
- Revenue
- BEAM $60,272,000.00
- VITL $657,947,000.00
- Revenue This Year
- BEAM N/A
- VITL $25.34
- Revenue Next Year
- BEAM $17.18
- VITL $19.58
- P/E Ratio
- BEAM N/A
- VITL $42.44
- Revenue Growth
- BEAM N/A
- VITL 21.49
- 52 Week Low
- BEAM $13.53
- VITL $27.91
- 52 Week High
- BEAM $35.25
- VITL $48.26
- Technical
- Relative Strength Index (RSI)
- BEAM 39.16
- VITL 74.62
- Support Level
- BEAM $16.65
- VITL $35.40
- Resistance Level
- BEAM $21.40
- VITL $47.85
- Average True Range (ATR)
- BEAM 1.00
- VITL 1.91
- MACD
- BEAM -0.35
- VITL 1.09
- Stochastic Oscillator
- BEAM 13.89
- VITL 94.21
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).